Journal of Clinical Oncology

Vol. 44, Issue 19_suppl Issue 19_suppl 2026
340
Articles

Articles in this Issue

Survivorship care planning and psychosocial outcomes in cervical cancer caregivers.

Priyadharshini Mari, Deepak Saini, Abhishek Shankar Jul 01, 2026 pp. 214-214 10.1200/jco.2026.44.19_suppl.214

214 Background: Survival in Cervical Cancer has improved substantially, increasing reliance on informal caregivers through...

Comparative effectiveness of different interventions in metastatic melanoma: A network meta-analysis.

Sami Salahia Jul 01, 2026 pp. 294-294 10.1200/jco.2026.44.19_suppl.294

294 Background: Multiple therapeutic options are available for metastatic melanoma, including immune checkpoint in...

Tislelizumab in combination with carboplatin and albumin–binding paclitaxel for neoadjuvant therapy in head and neck squamous cell carcinoma: A prospective, phase II clinical study.

Haotian Cao, Jinsong Li, Liansheng Wang et al. Jul 01, 2026 pp. 226-226 10.1200/jco.2026.44.19_suppl.226

226 Background: Surgery followed by adjuvant therapy remains the standard treatment for locally advanced head and neck squ...

Evaluating a hybrid AI-powered digital health guide to improve informed decision making and streamline access to genetic testing for hereditary cancer.

Anita Kinney, Samuel Tundealao, Emily Heidt et al. Jul 01, 2026 pp. 319-319 10.1200/jco.2026.44.19_suppl.319

319 Background: Despite expanded testing guidelines, lower costs, and clear clinical utility, uptake of genetic testing re...

Long-term outcomes and patterns of recurrence in mucinous rectal adenocarcinoma: A KCRG multicenter study.

Takumi Kozu, Ryosuke Okamura, Tomoaki Okada et al. Jul 01, 2026 pp. 123-123 10.1200/jco.2026.44.19_suppl.123

123 Background: Mucinous adenocarcinoma is a poor prognostic indicator of colorectal cancer. Due to its rarity, mucinous c...

Doxycycline modulation of the CD39/CD73–adenosine axis to enhance CD8⁺ T cell and M1 macrophage immunity in patient-derived breast cancer samples.

Parameswar Dalai, Reena Agrawal Rajput, Parloop Bhatt Jul 01, 2026 pp. 33-33 10.1200/jco.2026.44.19_suppl.33

33 Background: The CD39/CD73–adenosine axis functions as a metabolic immune checkpoint in breast cancer by converting extr...

Characterizing plasma circulating tumor RNA (ctRNA) landscape in advanced NSCLC: Preliminary insights into treatment resistance and tumor microenvironment.

Michelle Pek, Jonathan Poh, Min-Han Tan Jul 01, 2026 pp. 167-167 10.1200/jco.2026.44.19_suppl.167

167 Background: Plasma circulating tumor RNA (ctRNA) is currently used for gene fusion detection in non–small cell lung ca...

Disease-specific safety risks in oncology large language models: A multi-axis evaluation across solid tumor subtypes.

Yan Leyfman, Connor Yost, Helena S. Coloma et al. Jul 01, 2026 pp. 19-19 10.1200/jco.2026.44.19_suppl.19

19 Background: Large language models (LLMs) are increasingly explored for oncology clinical decision support; however, saf...

Simulating expert oncologist-to-oncologist thinking and behavior: Multi-agent AI for precision oncology collaboration.

Deva Datta Reddy Jyothi, Samyukta Jytohi, Devarshini Jyothi Jul 01, 2026 pp. 20-20 10.1200/jco.2026.44.19_suppl.20

20 Background: Collaborative oncologist decision-making—via tumor boards, subspecialty consultation, and second opinions—f...

Comparative efficacy and safety of first-line maintenance therapies in advanced ovarian cancer: A biomarker-stratified Bayesian network meta-analysis of 16 phase 3 trials.

Rahul Falodia, Shankar Biswas Jul 01, 2026 pp. 213-213 10.1200/jco.2026.44.19_suppl.213

213 Background: The integration of poly(ADP-ribose) polymerase inhibitors (PARPi), immune checkpoint inhibitors (ICI), and...

Mortality trends and disparities in bone-metastatic prostate cancer in the United States, 1999–2024: A CDC WONDER analysis.

Vishan Das, Kanza Atif, Mazhar Ali et al. Jul 01, 2026 pp. 189-189 10.1200/jco.2026.44.19_suppl.189

189 Background: In United States, mortality trends for bone-metastatic prostate cancer remain incompletely characterized....

INAVO120 phase 3 trial: Subgroup analyses of Asian patients (pts) with <i>PIK3CA</i> -mutated (mut), hormone receptor-positive, HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC) treated with inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV).

Yoon Sim Yap, Huiping Li, Qingyuan Zhang et al. Jul 01, 2026 pp. 28-28 10.1200/jco.2026.44.19_suppl.28

28 Background: INAVO is an oral, highly potent, and selective PI3Kα inhibitor that also promotes mut p110α degradation. In...

Real-world artificial intelligence use in oncology practice: High clinician verification amid critical governance gaps.

Yan Leyfman, Connor Yost, Soumiya Nadar et al. Jul 01, 2026 pp. 353-353 10.1200/jco.2026.44.19_suppl.353

353 Background: Artificial intelligence (AI) tools are rapidly entering oncology practice. However, real-world data descri...

Testosterone deprivation or androgen receptor inhibition effect on endothelial glycocalyx injury in prostate cancer.

Naoki Fujita, Takuma Narita, Yuki Tobisawa et al. Jul 01, 2026 pp. 193-193 10.1200/jco.2026.44.19_suppl.193

193 Background: Endothelial glycocalyx, which coats the luminal surface of vascular endothelial cells, plays a pivotal rol...

CAR-NK cell therapy in colorectal cancer: A systematic review of early clinical signals and translational strategies.

Muhammad Alifian Remifta Putra, Farida Farah Adibah, Marcello Mikhael Kadharusman Jul 01, 2026 pp. 79-79 10.1200/jco.2026.44.19_suppl.79

79 Background: Colorectal cancer (CRC) demonstrates limited responsiveness to current immune checkpoint inhibitors...

Clinicopathologic features, treatment patterns, and survival outcomes of glycogen-rich clear cell carcinoma of the breast: A National Cancer Database Analysis.

Cher Ying Foo, Ojasav Sehrawat, Waqar Haque et al. Jul 01, 2026 pp. 40-40 10.1200/jco.2026.44.19_suppl.40

40 Background: Glycogen-rich clear cell carcinoma (GRCC) of the breast is rare subtype of invasive breast carcinoma, chara...

Hallmarks based stratification of locally advanced GBC according to response to first-line chemotherapy in advanced gallbladder cancer (GBC).

Sushma Agrawal, Raghunath M., Ojas Gupta et al. Jul 01, 2026 pp. 309-309 10.1200/jco.2026.44.19_suppl.309

309 Background: GBC is a heterogenous disease with high mortality rate. While platinum-based chemotherapy remains the SOC...

Decision-making in cancer during pregnancy: Real-world management patterns and outcomes from Nepal.

Poonam Lama Jul 01, 2026 pp. 302-302 10.1200/jco.2026.44.19_suppl.302

302 Background: Cancer occurring one in every 1,000 pregnancies is rare and poses immense diagnostic and management challe...

Health related quality of life (HRQOL) and early clinical outcomes of high - very high risk prostate cancer treated with linac based stereotactic body radiotherapy (SBRT) and long term androgen deprivation therapy (ADT).

Jay Prakash Sahu, Trinanjan Basu, Komal Jaikishan Parwani et al. Jul 01, 2026 pp. 191-191 10.1200/jco.2026.44.19_suppl.191

191 Background: Stereotactic body radiotherapy (SBRT) in NCCN high-risk (HR) and very high-risk (VHR) prostate cancer is e...

Adebrelimab plus interventional and targeted therapy for unresectable hepatocellular carcinoma: A single-arm, real-world study.

Chenchen Zhao, Dongmei Quan, Jiye Song et al. Jul 01, 2026 pp. 107-107 10.1200/jco.2026.44.19_suppl.107

107 Background: Systemic therapy with immune checkpoint inhibitors (ICIs) and targeted agents, in combination with interve...

Neoadjuvant toripalimab combined with TIP chemotherapy for locally advanced penile squamous cell carcinoma: A multicenter prospective, single-arm, phase II clinical trial.

Ting Xue, Longbin Xiong, Qing Yang et al. Jul 01, 2026 pp. 178-178 10.1200/jco.2026.44.19_suppl.178

178 Background: The neoadjuvant regimen of paclitaxel, ifosfamide, and platinum (TIP) regimen is recommended for local adv...

Adebrelimab plus apatinib for maintenance treatment of extensive-stage small cell lung cancer after first-line induction with adebrelimab plus chemotherapy (CLOG2402-ADAPT): A multi-center, single-arm, phase II trial.

Lingyun Zhang, Xiuna Zhang, Jinhua Piao et al. Jul 01, 2026 pp. 271-271 10.1200/jco.2026.44.19_suppl.271

271 Background: Immune checkpoint inhibitors (PD-1/PD-L1) combined with chemotherapy have become the standard first-line t...

Implementation of a patient-reported symptom tool in low-resource settings with high demand for services: A pilot feasibility study (PROMISE-Pilot).

Jayson L. Co, Kevin Lee Min Chua, Durgesh Innani et al. Jul 01, 2026 pp. 352-352 10.1200/jco.2026.44.19_suppl.352

352 Background: Patients often experience cancer and treatment-related symptoms that can be under-elicited and under-repor...

Strengthening nurse-led clinical breast examination (CBE) screening through quality improvement: A prospective implementation study from a tertiary hospital in eastern India.

Dr. Kahkasha, Rakhi Gaur Jul 01, 2026 pp. 315-315 10.1200/jco.2026.44.19_suppl.315

315 Background: India, representing nearly one-fifth of the global female population, faces a rapidly increasing breast ca...

Real-world incidence and spectrum of immune-related toxicity in cancer patients: A registry cohort data from a Central Coast Cancer Centre.

Dmitrii Shek, Matthew Chan, Fiona Dixon et al. Jul 01, 2026 pp. 318-318 10.1200/jco.2026.44.19_suppl.318

318 Background: Immune-checkpoint inhibitors (ICIs) have transformed outcomes across a broad range of solid malignancies,...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page